<unk>  (ACP-103; BVF-036), sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being studied for the treatment of Alzheimer’s disease psychosis, schizophrenia, agitation, and major depressive disorder. Unlike other antipsychotics,<unk>  is not a dopamine receptor antagonist.
Pimavanserin
Adatanserin
Ketanserin
Blonanserin
Nabilone
Flibanserin
Seltorexant
Suvorexant